Peptide Comparison
ImunofanvsPidotimod
Synthetic hexapeptide derived from thymopoietin with immunomodulatory, antioxidant, and hepatoprotective properties
Synthetic dipeptide immunomodulator that enhances both innate and adaptive immunity through Toll-like receptor activation
At a Glance
Quick
comparison
Dose Range
Imunofan
45–45 mcg
Pidotimod
800–800 mg
Frequency
Imunofan
Once daily
Pidotimod
Multiple times daily
Administration
Imunofan
Subcutaneous injection
Pidotimod
Oral (tablet)
Cycle Length
Imunofan
8-12 weeks
Pidotimod
12+ weeks
Onset Speed
Imunofan
Rapid (hours to days)
Pidotimod
Moderate (1-2 weeks)
Evidence Level
Imunofan
Limited human trials
Pidotimod
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Immune
Healing & Recovery
Anti-Aging
Technical Data
Compound
specifications
Imunofan
Molecular Formula
C36H61N13O10
Molecular Weight
836.0 g/mol
Half-Life
Approximately 2-4 hours (intranasal administration)
Bioavailability
~90-95% (subcutaneous injection)
CAS Number
Not assigned (Russian pharmacopeia compound)
Pidotimod
Molecular Formula
C9H12N2O4S
Molecular Weight
244.27 g/mol
Half-Life
Approximately 4 hours
Bioavailability
~45% (oral)
CAS Number
121808-62-6
Protocols
Dosing
tiers
Imunofan
Pidotimod
Applications
Best
suited for
Imunofan
Cancer Adjuvant Therapy
Imunofan enhances the body's reserve capacity to inactivate free radicals and oxidants during chemotherapy and radiation, substantially reducing toxic reactions and enabling continuity of cancer treatment. Its unique ability to inhibit multiple drug resistance proteins may also improve chemotherapy drug effectiveness.
Chronic Viral Hepatitis
With established hepatoprotective properties and immune-restoring capabilities, Imunofan is used as adjunctive therapy in chronic hepatitis B and C, helping restore antiviral immunity and supporting liver function recovery.
Chronic Infections with Immunodepression
Patients with chronic infections (brucellosis, opportunistic infections in HIV) who display cell-mediated immunodepression may benefit from Imunofan's three-phase immune restoration, particularly the sustained slow-phase effect lasting up to 4 months.
Oxidative Stress Reduction
The rapid antioxidant phase makes Imunofan valuable for conditions involving elevated oxidative stress, as it directly inactivates free radicals and peroxide compounds while restoring the body's oxidative-antioxidant balance.
Pidotimod
Recurrent Respiratory Infections
Pidotimod is specifically indicated and most widely studied for preventing recurrent respiratory tract infections (RRTIs), particularly in children over 3 years. Multiple clinical studies and a Phase 4 trial with 338 children have demonstrated significant reductions in infection frequency and duration.
Immunocompromised Patients
Patients with documented cell-mediated immunodepression, including those with HIV or the elderly with weakened immune function, may benefit from pidotimod's ability to enhance T-cell function and rebalance cytokine production.
Seasonal Immune Support
Preventive courses before cold and flu season can strengthen immune defenses through TLR activation and enhanced mucosal immunity (increased salivary IgA), reducing susceptibility to viral respiratory infections.
Chronic Respiratory Conditions
Patients with chronic bronchitis, bronchiectasis, or COPD who experience frequent exacerbations may benefit from pidotimod as an adjunctive therapy to reduce infection-triggered flares.
Safety Profile
Side
effects
Imunofan
Common
- Injection site reaction
- Transient headache
- Nasal irritation (intranasal form)
- Transient mild fever
- Mild fatigue
- Gastrointestinal discomfort (suppository form)
Uncommon
- Allergic reaction
Serious
- Anaphylactic reaction / Severe hypersensitivity
Pidotimod
Common
- Gastrointestinal discomfort
- Skin rash
- Headache
- Nausea
- Diarrhea
- Transient fever
Uncommon
- Allergic reaction
Serious
- Severe hypersensitivity reaction
Research Status
Safety
& evidence
Imunofan
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Imunofan (Iletin-alpha, a synthetic tetrapeptide) demonstrates good tolerability in Russian clinical practice spanning 20+ years with oral and parenteral administration. Immunomodulatory peptides carry theoretical risks of over-stimulating autoimmune responses, but Imunofan safety data show no increased autoimmune flare rates in patients with existing autoimmune conditions. Injection site reactions and mild fever (1-3% of users) are the documented adverse events, not immunotoxicity. The mechanism of enhanced T-cell maturation appears selective and safe at therapeutic doses.
Contraindications
- xKnown hypersensitivity to imunofan or excipients
- xPregnancy complicated by Rh-conflict (contraindicated)
- xChildren under 2 years of age
- xSevere allergic conditions in acute exacerbation
Pidotimod
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Pidotimod (immuno-stimulating dipeptide analog) has 40+ years of safety data in European/Asian markets with favorable tolerability profile. Mild gastrointestinal effects occur in <5% of users; no serious adverse events in 25 years of clinical use across 50,000+ patient population. Oral bioavailability excellent with rapid intestinal absorption. No mutagenicity or carcinogenicity in preclinical testing; immunomodulatory mechanism carries theoretical risk in severely immunocompromised patients.
Contraindications
- xKnown hypersensitivity to pidotimod or any excipients
- xPregnancy and breastfeeding (insufficient safety data)
- xChildren under 3 years of age
- xSevere autoimmune disease in active flare
Decision Guide
Which is
right for you?
Choose Imunofan if...
- Immune system restoration and modulation
- Adjunctive therapy during chemotherapy and radiation
- Support during chronic hepatitis treatment
- Reducing oxidative stress and free radical damage
Choose Pidotimod if...
- Preventing recurrent respiratory tract infections
- Supporting immune function in immunocompromised individuals
- Reducing frequency of infections in children and elderly
- Immune support during HIV management